NCBiotech News

Durham-based biotechnology startup Tavros Therapeutics will partner with Bayer AG subsidiary Vividion Therapeutics to find new targets and treatments for cancer.

PPD, the Wilmington-based clinical research business of Thermo Fisher Scientific, has been awarded a 10-year NCI contract to support cancer clinical trials.

Durham-based Praetego, a pharmaceutical company focused on treating neurodegenerative diseases related to aging, has received a $2.5 millionNIH grant to advance its lead drug candidate against Alzheimer’s disease.

Curie Co, an early stage enzymes company based in New York City, has relocated to Research Triangle Park and hired an industry veteran with North Carolina ties as its chief technology officer.

The Mushroom Meat Company, a Chapel Hill food tech startup, is winning kudos for its plant-based meat substitutes in a fast-growing market segment.

Central Carolina Community College recently welcomed its first Biotechnology Pathway Navigator to give BioWork and biotechnology students a leg up when pursuing a career in biomanufacturing and the life sciences.

Georgia placental biologics company MIMEDX will have a laboratory in the RegeneratOR Innovation Accelerator in Winston-Salem’s Innovation Quarter.

Cary-based Chiesi USA continues to expand its diversity, equity and inclusion efforts through partnerships and research funding that directly support North Carolina students and researchers.

Johnston County commissioners have approved performance-based economic development incentives in support of anticipated new investments during the coming 12 years by global biomanufacturing giant Novo Nordisk.

BD, a global medical device manufacturer with four North Carolina sites, today announced plans for a potential $30 million expansion of its Four Oaks campus that will create 22 new jobs.

A statewide coalition led by NCBiotech has received a Phase 2 award totaling nearly $25 million from the U.S. EDA's Build Back Better Regional Challenge.

Durham's BioCryst has received the FDA's orphan drug designation for its experimental therapy to treat a rare hereditary disease called fibrodysplasia ossificans progressive.

Durham-based 410 Medical has received up to nearly $2 million in U.S. military funding to develop two new versions of LifeFlow, its medical device for treating life-threatening low blood pressure, shock and sepsis in critically ill patients.

RTP Biopesticides developer Vestaron has raised $10 million in additional financing to expand its scope to more crops and different insects.

Army veteran Diane Zambrano exemplifies how earning BioWork certification at Johnston Community College laid the groundwork for career steps leading to her dream job.